Although the use of immortalized cell lines with RET mutations may represent a limitation, these data provide a strong rationale to define in the future the potential antitumor activity of drugs targeting FGFR/VEGFR system particularly in patients with RET-negative MTC. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.